Clinical Trial Update: Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial investigating functional neuroimaging of alcoholism vulnerability using the mGluR5 inhibitor mavoglurant to probe glutamate signal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder

Drugs mentioned

• Mavoglurant (AFQ056) (mavoglurant)

Snippet

Sponsor: Yale University | Conditions: Familial Alcoholism Vulnerability | EARLY_Phase 1 | Status: RECRUITING